8-K
Adaptive Biotechnologies Corp (ADPT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 12, 2020
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
| Washington | 001-38957 | 27-0907024 |
|---|---|---|
| (State or Other Jurisdiction<br><br><br>of Incorporation) | (Commission File Number) | (IRS Employer<br><br><br>Identification No.) |
| 1551 Eastlake Avenue East, Suite 200,<br><br><br>Seattle, Washington | 98102 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (206) 659-0067
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br><br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, par value $0.0001 per share | ADPT | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Shareholders
On June 12, 2020, Adaptive Biotechnologies Corporation held its Annual Meeting of Shareholders. The following nominees were elected as directors, each to hold office until the annual meeting of shareholders on the date shown below or until his successor is elected and qualified, by the vote set forth below:
| Nominee | Class ^(1)^ | For | Withhold | Broker<br>Non-Votes |
|---|---|---|---|---|
| David Goel | I | 72,878,339 | 11,385,039 | 16,206,222 |
| Robert Hershberg, PhD, MD | I | 72,889,859 | 11,373,519 | 16,206,222 |
| Andris Zoltners, PhD | I | 72,363,340 | 11,900,038 | 16,206,222 |
| (1) | The terms of each of the Class I directors will expire as of the 2023 annual meeting. | |||
| --- | --- |
The appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending December 31, 2020 was ratified by the vote set forth below:
| For | Against | Abstain |
|---|---|---|
| 100,160,546 | 303,466 | 5,588 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Adaptive Biotechnologies Corporation | ||
|---|---|---|
| Date: June 16, 2020 | By: | /s/ Chad Cohen |
| Chad Cohen | ||
| Chief Financial Officer |